Expertise in
13
conditions

Dr. Hiram A. Gay

Radiation Oncology
Washington University
4921 Parkview Pl, 
Saint Louis, MO 
Clinical Trials:Currently Recruiting for 2 Trials
Accepting New Patients
Expertise in
13
conditions
Washington University
4921 Parkview Pl, 
Saint Louis, MO 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Hiram Gay is a Radiation Oncologist in Saint Louis, Missouri. Dr. Gay is highly rated in 13 conditions, according to our data. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Laryngeal Cancer, Gastrostomy, and Prostatectomy. Dr. Gay is currently accepting new patients.

His clinical research consists of co-authoring 138 peer reviewed articles and participating in 13 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
University Of Puerto Rico School Of Medicine
Specialties
Radiation Oncology
Licenses
Radiology in MO
Hospital Affiliations
Parkland Health Center
Barnes-Jewish West County Hospital
Barnes Jewish Hospital
Memorial Hospital
Missouri Baptist Medical Center
Languages Spoken
English
Spanish
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Cox Health
  • EPO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

WASHINGTON UNIVERSITY
4921 Parkview Pl, Saint Louis, MO 63110

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

A Phase I and Randomized Phase II Trial of Radium-223 Dichloride, M3814, &Amp; Avelumab in Advanced Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
A Phase I and Randomized Phase II Trial of Radium-223 Dichloride, M3814, &Amp; Avelumab in Advanced Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
Enrollment Status: Recruiting
Publish Date: June 04, 2025
Intervention Type: Drug, Procedure, Other, Radiation
Study Drugs: Avelumab, Peposertib, Radium-223
Study Phase: Phase 1/Phase 2
Non-Randomized Phase 2 Trial of Three Schedules of CUE-101 Administered Before Surgery or Definitive Chemoradiation Therapy in HLA-A*0201 Positive Patients With Locally Advanced, HPV16-Positive Oropharyngeal Squamous-Cell Carcinoma
Non-Randomized Phase 2 Trial of Three Schedules of CUE-101 Administered Before Surgery or Definitive Chemoradiation Therapy in HLA-A*0201 Positive Patients With Locally Advanced, HPV16-Positive Oropharyngeal Squamous-Cell Carcinoma
Enrollment Status: Recruiting
Publish Date: February 06, 2025
Intervention Type: Drug
Study Drug: CUE-101
Study Phase: Phase 2
A Phase 1/2 Study of Combination Olaparib and Radium-223 in Men With Metastatic Castration-Resistant Prostate Cancer With Bone Metastases (COMRADE)
A Phase 1/2 Study of Combination Olaparib and Radium-223 in Men With Metastatic Castration-Resistant Prostate Cancer With Bone Metastases (COMRADE)
Enrollment Status: Active_not_recruiting
Publish Date: May 15, 2025
Intervention Type: Other, Procedure, Drug, Radiation
Study Drugs: Olaparib, Radium-223
Study Phase: Phase 1/Phase 2
A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer (BALANCE*)
A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer (BALANCE*)
Enrollment Status: Active_not_recruiting
Publish Date: May 07, 2025
Intervention Type: Other, Radiation, Drug
Study Drug: Apalutamide
Study Phase: Phase 2
Los Tres Paso Trial: Step One - Neoadjuvant Palbociclib Monotherapy, Step Two - Concurrent Chemoradiation Therapy, and Step Three - Adjuvant Palbociclib Monotherapy in Patients With p16INK4a Negative, HPV-Unrelated Head and Neck Squamous Cell Carcinoma
Los Tres Paso Trial: Step One - Neoadjuvant Palbociclib Monotherapy, Step Two - Concurrent Chemoradiation Therapy, and Step Three - Adjuvant Palbociclib Monotherapy in Patients With p16INK4a Negative, HPV-Unrelated Head and Neck Squamous Cell Carcinoma
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2025
Intervention Type: Drug, Procedure, Radiation
Study Drugs: Palbociclib, Cetuximab, Cisplatin
Study Phase: Phase 2
Novel Approach of Pulsed Abraxane and Radiotherapy for Improving and Maintaining Ambulation After Cancer-Related Cord Compression
Novel Approach of Pulsed Abraxane and Radiotherapy for Improving and Maintaining Ambulation After Cancer-Related Cord Compression
Enrollment Status: Terminated
Publish Date: February 04, 2025
Intervention Type: Radiation, Drug
Study Phase: Phase 2
Immunotherapy With MK-3475 in Locoregionally Advanced, Surgically Resectable Head and Neck Squamous Cell Carcinoma
Immunotherapy With MK-3475 in Locoregionally Advanced, Surgically Resectable Head and Neck Squamous Cell Carcinoma
Enrollment Status: Active_not_recruiting
Publish Date: January 14, 2025
Intervention Type: Radiation, Procedure, Biological, Drug
Study Drugs: Pembrolizumab, Cisplatin
Study Phase: Phase 2
Phase II Non-Randomized Three Arm Trial of Induction Chemotherapy With Nab-Paclitaxel and Cisplatin (AP: Arms 1 and 3) or Single Agent Nab-paclitaxel (A: Arm 2) as Induction Therapy Followed by Definitive Concurrent Chemoradiation for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC): The APA Trial.
Phase II Non-Randomized Three Arm Trial of Induction Chemotherapy With Nab-Paclitaxel and Cisplatin (AP: Arms 1 and 3) or Single Agent Nab-paclitaxel (A: Arm 2) as Induction Therapy Followed by Definitive Concurrent Chemoradiation for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC): The APA Trial.
Enrollment Status: Completed
Publish Date: December 27, 2024
Intervention Type: Drug, Radiation, Biological
Study Drugs: Nab-Paclitaxel, Cisplatin, Cetuximab
Study Phase: Phase 2
STEEL: A Randomized Phase II Trial of Salvage Radiotherapy With Standard vs Enhanced Androgen Deprivation Therapy (With Enzalutamide) in Patients With Post-Prostatectomy PSA Recurrences With Aggressive Disease Features
STEEL: A Randomized Phase II Trial of Salvage Radiotherapy With Standard vs Enhanced Androgen Deprivation Therapy (With Enzalutamide) in Patients With Post-Prostatectomy PSA Recurrences With Aggressive Disease Features
Enrollment Status: Active_not_recruiting
Publish Date: October 16, 2024
Intervention Type: Radiation, Drug
Study Drugs: Enzalutamide, Bicalutamide, GnRH analog
Study Phase: Phase 2
Phase II Trial of Surgery Followed by Risk-Directed Post-Operative Adjuvant Therapy for HPV-Related Oropharynx Squamous Cell Carcinoma: The Minimalist Trial (MINT)
Phase II Trial of Surgery Followed by Risk-Directed Post-Operative Adjuvant Therapy for HPV-Related Oropharynx Squamous Cell Carcinoma: The Minimalist Trial (MINT)
Enrollment Status: Active_not_recruiting
Publish Date: August 15, 2024
Intervention Type: Other, Drug, Radiation, Procedure
Study Drug: Cisplatin
Study Phase: Phase 2
Palliative Expeditiously Adaptive Quad Shot Radiation Therapy (PEAQ-RT): A Pilot Study of Consolidated Simulation and Target Identification of Quad Shot Radiation Therapy Using an Adaptive Radiotherapy Workflow With a Novel Ring Gantry Radiotherapy Device
Palliative Expeditiously Adaptive Quad Shot Radiation Therapy (PEAQ-RT): A Pilot Study of Consolidated Simulation and Target Identification of Quad Shot Radiation Therapy Using an Adaptive Radiotherapy Workflow With a Novel Ring Gantry Radiotherapy Device
Enrollment Status: Completed
Publish Date: December 08, 2023
Intervention Type: Radiation, Device
Study Phase: Not Applicable
Evaluation of TraceIT Tissue Marker to Mark the Primary Resection Bed Margins of Oropharyngeal Cancers: a Pilot Study
Evaluation of TraceIT Tissue Marker to Mark the Primary Resection Bed Margins of Oropharyngeal Cancers: a Pilot Study
Enrollment Status: Terminated
Publish Date: July 12, 2022
Intervention Type: Device
Study Phase: Not Applicable
Remote Collection of Patient Reported Toxicity Using SMS Text Messaging
Remote Collection of Patient Reported Toxicity Using SMS Text Messaging
Enrollment Status: Completed
Publish Date: August 25, 2021
Intervention Type: Other
View 11 Less Clinical Trials

138 Total Publications

Evolution and Recent Radiation Therapy Advancement in Uganda: A Precedent on How to Increase Access to Quality Radiotherapy Services in Low- and Middle-Income Countries.
Evolution and Recent Radiation Therapy Advancement in Uganda: A Precedent on How to Increase Access to Quality Radiotherapy Services in Low- and Middle-Income Countries.
Journal: JCO global oncology
Published: January 30, 2025
Similar Doctors
Expertise in
34
conditions
Dr. Jiayi T. Huang
Radiation Oncology
Expertise in
34
conditions
Dr. Jiayi T. Huang
Radiation Oncology

Washington University

4921 Parkview Pl, 
Saint Louis, MO 
 (0.1 mi)
314-362-9715
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Jiayi Huang is a Radiation Oncologist in Saint Louis, Missouri. Dr. Huang is highly rated in 34 conditions, according to our data. His top areas of expertise are Astrocytoma, Oligodendroglioma, Glioma, Tissue Biopsy, and Gamma Knife Radiosurgery. Dr. Huang is currently accepting new patients.

Expertise in
15
conditions
Dr. Perry W. Grigsby
Radiation Oncology
Expertise in
15
conditions
Dr. Perry W. Grigsby
Radiation Oncology
1 Barnes Jewish Hospital Plz, Dept Radiology, 
Saint Louis, MO 
 (0.2 mi)
314-362-7000
Languages Spoken:
English
See accepted insurances

Perry Grigsby is a Radiation Oncologist in Saint Louis, Missouri. Dr. Grigsby is highly rated in 15 conditions, according to our data. His top areas of expertise are Cervical Cancer, Thyroid Cancer, Papillary Thyroid Cancer, Follicular Thyroid Cancer, and Thyroidectomy.

Expertise in
9
conditions
Dr. Jeff M. Michalski
Radiation Oncology
Expertise in
9
conditions
Dr. Jeff M. Michalski
Radiation Oncology

Washington University

4921 Parkview Pl, 
Saint Louis, MO 
 (0.1 mi)
314-362-9715
Languages Spoken:
English, French
See accepted insurances
Accepting New Patients

Jeff Michalski is a Radiation Oncologist in Saint Louis, Missouri. Dr. Michalski is highly rated in 9 conditions, according to our data. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Muscle Invasive Bladder Cancer, Malignant Peripheral Nerve Sheath Tumor, and Prostatectomy. Dr. Michalski is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Gay's expertise for a condition
ConditionClose
View All 8 Advanced Conditions
View All 17 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile